Ocular dysfunction during the amytal suppression test.

J DeToledo; D B Smith; R Stanulis

doi:10.1016/0028-3932(93)90153-q

Home/Archive/PubMed

PubMed · 8232854

Ocular dysfunction during the amytal suppression test.

J DeToledo·D B Smith·R Stanulis

View original source ↗Export metadata ↓

Abstract

We assessed the following parameters of visual function in 16 patients during amytal suppression test (AST): pupillary light response, consensual reflex, pupillary symmetry, monocular reading and monocular visual recognition. Significant visual impairment in the eye ipsilateral to injection (EII) occurred in 7 of 16 patients ranging from blurring to complete, transient loss of vision. We conclude that visual dysfunction of the EII during the AST is common and represents an important component of the test. Intracarotid amytal reaches the EII via ophthalmic artery and probably impairs vision in the EII due to cycloplegia, iridoplegia and retinal suppression.

Explore related subjects

Amobarbital Eye Female Functional Laterality Humans Male Pupil Reflex, Pupillary Task Performance and Analysis Vision Disorders Comparative Study Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

J DeToledo, D B Smith, R Stanulis. 1993. Ocular dysfunction during the amytal suppression test.. https://doi.org/10.1016/0028-3932(93)90153-q

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Selective middle cerebral artery Wada tests for evaluation of motor representation.

Explore the source record for details and available documents.

Amobarbital↗

PubMed2003

Unsuspected atypical hemispheric dominance for language as determined by FMRI. Handedness: neural versus behavioral: the difference is measurable.

Explore the source record for details and available documents.

Amobarbital↗

PubMed2002

Barbiturates induce mitochondrial depolarization and potentiate excitotoxic neuronal death.

Barbiturates are widely used as anesthetics, anticonvulsants, and neuroprotective agents. However, barbiturates may also inhibit mitochondrial respiration, and mitochondrial inhibitors are known to potentiate NMDA receptor-mediated neurotoxicity. Here we used rat cortical cultures to examine the effect of barbiturates on neuronal mitochondria and responses to NMDA receptor stimulation. The barbiturates tested, secobarbital, amobarbital, and thiamylal, each potentiated NMDA-induced neuron death at barbiturate concentrations relevant to clinical and experimental use (100-300 microm). By using rhodamine-123 under quenching conditions, barbiturates in this concentration range were shown to depolarize neuronal mitochondria and greatly amplify NMDA-induced mitochondrial depolarization. Barbiturate-induced mitochondrial depolarization was increased by the ATP synthase inhibitor oligomycin, indicating that barbiturates act by inhibiting electron transport sufficiently to cause ATP synthase reversal. Barbiturates similarly amplified the effects of NMDA on cytoplasmic free calcium concentrations. The cell-impermeant barbiturate N-glucoside amobarbital did not influence mitochondrial potential or potentiate NMDA neurotoxicity or calcium responses. However, all of the barbiturates attenuated NMDA-induced calcium elevations and cell death when present at millimolar concentrations. Whole-cell patch-clamp studies showed that these effects may be attributable to actions at the cell membrane, resulting in a block of NMDA-induced current flux at millimolar barbiturate concentrations. Together, these findings reconcile previous reports of opposing effects on barbiturates on NMDA neurotoxicity and show that barbiturate effects on neuronal mitochondria can be functionally significant. Effects of barbiturates on neuronal mitochondria should be considered in experimental and clinical application of these drugs.

Amobarbital↗